4462 - Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer

Background

Lung cancer is the leading cause of cancer mortality worldwide with more than 2 million new cases and 1.8 million deaths in 2018. The TTR could be of use to objectively understand the clinical reality of lung cancer in Spain.

Methods

Observational cohort multicenter study performed in Spain. Enrollment took place between Aug’16 and Dec’18. Evaluation included a review of demographic data.

Results

6600 patients in 56 Spanish hospitals were included. Median age at diagnosis was 64 in advanced disease and 65 in early-stage. The majority of patients presented with advanced, stage III (n = 1874, 28.4%) or IV (n = 3446, 52.2%) at diagnosis, independently of gender (63.1% in males; 70.6% in females). There was a higher number of patients with no comorbidities at diagnosis in advanced disease than in early-stage (63.4% vs. 36.6%, p < 0.001) Significant differences (p < 0.001, unless indicated) observed between the two groups in the prevalence of cardiopathy, dyslipidemia (p = 0.043), COPD, hypercholesterolemia (p = 0.026), hypertension, nephropathy (p = 0.012), obesity (p = 0.007) and vasculopathy. Prevalence of symptoms (cough, pain, dyspnea, hemoptysis, weight loss, anorexia, and asthenia) was higher (p < 0.001) in advanced disease. No association found between professional occupation and stage at diagnosis, but according to exposure to carcinogenic compounds. A higher % of patients with advanced disease was observed over exposed to arsenic compounds (87.5% vs. 65.1%, p = 0.02) and acrylonitrile (75.0% vs. 65.1%, p = 0.02). Early-stage disease more prevalent among patients exposed to asbestos (47.5% vs. 34.9%, p = 0.02), radon/silica (47.4% vs. 34.9%, p = 0.02) and paintings (38.1% vs. 34.9%, p = 0.02) and diesel smoke (38.2% vs. 34.9%, p = 0.02) More patients with personal history of cancer had early-stage vs advanced disease (47.6% vs. 34.9%, p < 0.001); no differences found in stage according to family history of cancer.

Conclusions

The RTT provides information on comorbidities, risk associations, personal and family history of cancer necessary for the knowledge of lung cancer in real life, which could even be useful when planning the analysis of national health policies.

Clinical trial identification

NCT02941458.

Editorial acknowledgement

Legal entity responsible for the study

Spanish Lung Cancer Group.

Funding

Novartis, MSD, Lilly.

Disclosure

M. Provencio: Advisory / Consultancy: BMS; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim. All other authors have declared no conflicts of interest.